CRISPR Therapeutics (CRSP) stock Forecast for 2022 – 2026
Last update: 05-21-2022, 7:46Sector: Healthcare
The share price of CRISPR Therapeutics AG (CRSP) now
What analysts predict:: $121.86
52-week high/low: $169.76 / $42.51
50/200 Day Moving Average: $58.88 / $82.8
This figure corresponds to the average price over the previous 50/200 days. For CRISPR Therapeutics stocks, the 50-day moving average is the resistance level today.
For CRISPR Therapeutics stocks, the 200-day moving average is the resistance level today.
Are you interested in CRISPR Therapeutics AG stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the CRISPR Therapeutics stock price in 2022, 2023, 2024, 2025, 2026. How much will one CRISPR Therapeutics share be worth in 2022 - 2026?
When should I take profit in CRISPR Therapeutics stock? When should I record a loss on CRISPR Therapeutics stock? What are analysts' forecasts for CRISPR Therapeutics stock? What is the future of CRISPR Therapeutics stock?
We forecast CRISPR Therapeutics stock performance using neural networks based on historical data on CRISPR Therapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
CRISPR Therapeutics stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2022, 2023, 2024, 2025 and 2026)
The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for CRISPR Therapeutics shares. This happens once a day.
Historical and forecast chart of CRISPR Therapeutics stock
The chart below shows the historical price of CRISPR Therapeutics stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the CRISPR Therapeutics stock price can be found in the table below.
Long-term forecasts by years.
CRISPR Therapeutics daily forecast for a month
CRISPR Therapeutics Daily Price Targets
CRISPR Therapeutics Stock Forecast 05-23-2022.
Pessimistic target level: 56.98
Optimistic target level: 59.37
CRISPR Therapeutics Stock Forecast 05-24-2022.
Pessimistic target level: 56.08
Optimistic target level: 59.09
CRISPR Therapeutics Stock Forecast 05-25-2022.
Pessimistic target level: 54.61
Optimistic target level: 57.77
CRISPR Therapeutics Stock Forecast 05-26-2022.
Pessimistic target level: 54.55
Optimistic target level: 57.41
CRISPR Therapeutics Stock Forecast 05-27-2022.
Pessimistic target level: 55.00
Optimistic target level: 57.65
CRISPR Therapeutics Stock Forecast 05-28-2022.
Pessimistic target level: 55.44
Optimistic target level: 58.39
CRSP (CRSP) Monthly Stock Prediction for 2022
CRISPR Therapeutics forecast for this year
CRISPR Therapeutics Stock Prediction for Jun 2022
An downtrend is forecast for this month with an optimal target price of $54.0964. Pessimistic: $47.60. Optimistic: $59.20
CRISPR Therapeutics Stock Prediction for Jul 2022
An uptrend is forecast for this month with an optimal target price of $54.7023. Pessimistic: $48.05. Optimistic: $60.83
CRISPR Therapeutics Stock Prediction for Aug 2022
An uptrend is forecast for this month with an optimal target price of $57.7656. Pessimistic: $50.65. Optimistic: $61.83
CRISPR Therapeutics Stock Prediction for Sep 2022
An downtrend is forecast for this month with an optimal target price of $56.6565. Pessimistic: $49.59. Optimistic: $61.10
CRISPR Therapeutics Stock Prediction for Oct 2022
An uptrend is forecast for this month with an optimal target price of $58.1975. Pessimistic: $54.19. Optimistic: $60.25
CRISPR Therapeutics Stock Prediction for Nov 2022
An downtrend is forecast for this month with an optimal target price of $58.1975. Pessimistic: $56.15. Optimistic: $62.57
CRISPR Therapeutics Stock Prediction for Dec 2022
An uptrend is forecast for this month with an optimal target price of $66.4849. Pessimistic: $60.95. Optimistic: $74.89
CRISPR Therapeutics (CRSP) Monthly Stock Prediction for 2023
CRISPR Therapeutics (CRSP) Monthly Stock Prediction for 2024
CRISPR Therapeutics (CRSP) Monthly Stock Prediction for 2025
CRISPR Therapeutics (CRSP) Monthly Stock Prediction for 2026
CRISPR Therapeutics information and performance
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
CRISPR Therapeutics Address
BAARERSTRASSE 14, ZUG, CH
Market Capitalization: 4 026 608 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: 391 481 000 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: 11.06
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: N/A
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 33.86
Trailing PE: 11.06
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: 23.36
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 1.773
Enterprise Value (EV) /Revenue
EV To EBITDA: 4.867
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 77457000
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.